Vericel Corporation (VCEL) NASDAQ
34.85
+2.03(+6.19%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
34.85
+2.03(+6.19%)
Currency In USD
| Previous Close | 32.82 |
| Open | 32.46 |
| Day High | 35.09 |
| Day Low | 32.01 |
| 52-Week High | 45.97 |
| 52-Week Low | 28.95 |
| Volume | 635,388.17 |
| Average Volume | 655,379 |
| Market Cap | 1.78B |
| PE | 81.05 |
| EPS | 0.43 |
| Moving Average 50 Days | 33.98 |
| Moving Average 200 Days | 35.36 |
| Change | 2.03 |
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility
GlobeNewswire Inc.
Mar 04, 2026 1:00 PM GMT
Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWI
Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
GlobeNewswire Inc.
Feb 12, 2026 1:30 PM GMT
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-yea
Vericel Announces Preliminary 2025 Financial Results and Business Updates
GlobeNewswire Inc.
Jan 13, 2026 2:00 PM GMT
Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in adv